Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

Alliance for Clinical Trials in Oncology: Clinical Trials & FDA Approval Profile

Alliance for Clinical Trials in Oncology (Global / Institutional) sponsors 56 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 47 active protocols (18 recruiting now), 3 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)10.7%
Median Closed Enrollment vs National (145 pts)84 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Alliance for Clinical Trials in Oncology
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)56
Active Pipeline (Recruiting Now)47 (18)
Completed vs Stopped Early3 / 6 (10.7%)
Median Closed Actual Enrollment84 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Alliance for Clinical Trials in Oncology
Hospital Research SiteLocationShared Protocols
University of Oklahoma Health Sciences CenterOklahoma City, OK39
Billings Clinic Cancer CenterBillings, MT39
Carle Cancer CenterUrbana, IL39

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Alliance for Clinical Trials in Oncology
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT04803201Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell LymphomaPhase IIRECRUITING
NCT06632977Targeted Treatment for Metastatic Prostate Cancer, The PREDICT TrialPhase IIRECRUITING
NCT07293247A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After TreatmentPhase IIRECRUITING
NCT07200830Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate CancerPhase IIIRECRUITING
NCT06661720Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney CaPhase IIIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Alliance for Clinical Trials in Oncology Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI